- Home
- LAR vs ABSI Comparison
LAR vs ABSI Comparison
Compare LAR & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAR
- ABSI
- Stock Information
- Founded
- LAR 2007
- ABSI 2011
- Country
- LAR Switzerland
- ABSI United States
- Employees
- LAR N/A
- ABSI N/A
- Industry
- LAR
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- LAR
- ABSI Health Care
- Exchange
- LAR NYSE
- ABSI Nasdaq
- Market Cap
- LAR 335.1M
- ABSI 338.0M
- IPO Year
- LAR N/A
- ABSI 2021
- Fundamental
- Price
- LAR $2.33
- ABSI $2.76
- Analyst Decision
- LAR Buy
- ABSI Strong Buy
- Analyst Count
- LAR 1
- ABSI 5
- Target Price
- LAR $3.00
- ABSI $8.40
- AVG Volume (30 Days)
- LAR 1.0M
- ABSI 3.9M
- Earning Date
- LAR 08-12-2025
- ABSI 08-13-2025
- Dividend Yield
- LAR N/A
- ABSI N/A
- EPS Growth
- LAR N/A
- ABSI N/A
- EPS
- LAR N/A
- ABSI N/A
- Revenue
- LAR N/A
- ABSI $4,815,000.00
- Revenue This Year
- LAR N/A
- ABSI $81.76
- Revenue Next Year
- LAR N/A
- ABSI $287.79
- P/E Ratio
- LAR N/A
- ABSI N/A
- Revenue Growth
- LAR N/A
- ABSI N/A
- 52 Week Low
- LAR $1.71
- ABSI $2.01
- 52 Week High
- LAR $3.96
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- LAR N/A
- ABSI 47.40
- Support Level
- LAR N/A
- ABSI $2.49
- Resistance Level
- LAR N/A
- ABSI $2.86
- Average True Range (ATR)
- LAR 0.00
- ABSI 0.16
- MACD
- LAR 0.00
- ABSI -0.01
- Stochastic Oscillator
- LAR 0.00
- ABSI 42.78
About LAR LITHIUM ARGENTINA AG
Lithium Argentina is a pure-play lithium producer. The company owns two neighboring lithium brine resources in northwest Argentina: Cauchari-Olaroz and Pastos Grandes. Cauchari-Olaroz entered production in 2023, while Pastos Grandes is still in development. Lithium Argentina plans for both resources to be fully integrated with onside downstream processing capabilities and will sell into the lithium chemical market.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.